Azabicyclic Compounds Targeting Alpha-7 Nicotinic Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for schizophrenia and neurodegenerative disorders, such as Alzheimer's disease, are limited in effectively addressing negative symptoms, cognitive deficits, and side effects, while also failing to improve cognitive function and delay institutionalization.
Innovation Solution
Development of compounds that act as α7 nicotinic receptor agonists and partial agonists, which selectively bind to the α7 receptor, potentially improving cognitive function, reducing inflammation, and modulating neurotransmitter release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antipsychotic agents are used to treat schizophrenia, then positive symptoms are reduced, but negative symptoms and cognitive deficits are not relieved
Solution Approach 1:
The patent changes the target receptor parameter from D2 dopamine receptor (current antipsychotics) to α7 nicotinic acetylcholine receptor (new compounds). This parameter change enables simultaneous improvement of positive, negative, and cognitive symptoms by targeting a different neurotransmitter system with distinct functional properties
Solution Approach 2:
The α7 nicotinic acetylcholine receptor agonist compounds are designed to provide multi-functional therapeutic effects: improving positive symptoms (delusions, hallucinations), negative symptoms (social withdrawal, anhedonia), and cognitive deficits (attention, working memory, executive function) through a single mechanism of action at the α7 receptor
2Reliability
If current antipsychotic agents are used to treat schizophrenia, then positive symptoms are reduced, but unwanted side effects occur
Solution Approach 1:
The patent changes the pharmacological target from D2 dopamine receptor to α7 nicotinic acetylcholine receptor, thereby maintaining antipsychotic efficacy while avoiding the side effect profile associated with dopamine antagonism, including extrapyramidal symptoms, tardive dyskinesia, and metabolic disturbances
3Productivity
If nicotine is used to improve cognitive function, then cognitive function is enhanced, but addiction and other harmful effects occur
Solution Approach 1:
The patent applies local quality by designing compounds that selectively target the α7 nicotinic acetylcholine receptor subtype rather than all nicotinic receptors. This selective localization of pharmacological action provides cognitive enhancement while minimizing the addictive properties and harmful effects associated with non-selective nicotine activity
Solution Approach 2:
The patent changes the receptor selectivity parameter from non-selective nicotinic receptor activation (nicotine) to selective α7 nicotinic acetylcholine receptor activation (compounds of formula I). This parameter change preserves the cognitive-enhancing effects while reducing addiction potential and harmful side effects
Data Source
AI summary
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.